Quellen:
1. Greff et al., 2023
Greff, C. et al. (2023). Inositol is an effective and safe treatment in polycystic ovary syndrome: A review of the evidence.
Journal of Ovarian Research, 16(1), 1–12.
2. Zhao et al., 2021
Zhao, H. et al. (2021). Comparative efficacy of oral insulin sensitizers (metformin, thiazolidinediones, inositol, and berberine) in improving endocrine and metabolic profiles in women with PCOS: A network meta-analysis.
Reproductive Biology and Endocrinology, 19(1), 1–14.
3. Kutenaei et al., 2021
Kutenaei, B.S. et al. (2021). The effects of myo-inositol vs. metformin on ovarian function in polycystic ovary syndrome.
Journal of Obstetrics and Gynaecology Research, 47(5), 1692–1701.
4. Zhang et al., 2022
Zhang, J. et al. (2022). Short-period administration of myo-inositol and metformin on hormonal and glycolipid profiles in patients with polycystic ovary syndrome.
Gynecological Endocrinology, 38(3), 215–221.
5. Mendoza, N. et al. (2019).
Comparison of the effect of two combinations of myo-inositol and D-chiro-inositol in women with polycystic ovary syndrome undergoing ICSI: A randomized controlled trial.
Clinical and Experimental Obstetrics & Gynecology, 46(1), 1–7.